C21 · Pharmaceuticals · United States
Obesity-approved GIP and GLP-1 agonist medicine spending growth
United States: 9.6 billion USD in 2025.
- 9.6 billion USD Latest · United States · 2025
- Annual Release cadence
- 1 Record · 1 region · 2025
Verified 17 Sep 2026 · 1 publisher · Next period 2026
The figure
One published observation so far. A chart follows as soon as a second period is published.
Obesity-approved GIP and GLP-1 agonist medicine spending growth
United States, 2025
Every record
1 record · 1 region · 2025. Each period links to its record: the value, its source evidence and original document.
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: IQVIA. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (IQVIA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Annual growth in medicine spending contributed by GIP and GLP-1 receptor agonists approved for obesity and related comorbidities.
- Measure
- One slice of Medicine spending ( form: growth, segment: obesity gip and glp 1 agonist ) . Total expenditure on pharmaceutical products and therapies. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| U.S. Medicine Use Trends 2026 | IQVIA | — | 1 |
Other slices of medicine spending
- Cell and gene therapy spending share by geography 2 cell and gene therapy
- Net medicine spending 2 net prices
- Net medicine spending growth rate 2 net prices
- Oncology medicine spending at list prices 2 list prices · oncology
- COVID-19 vaccines and therapeutics spending decline 1 covid 19 vaccines and therapeutics
- Cell and gene therapy share of medicine spending 1 cell and gene therapy
- Cell and gene therapy spending 1 cell and gene therapy
- Cell and gene therapy spending average annual growth rate 1 cell and gene therapy
- Cell and gene therapy spending growth rate 1 cell and gene therapy
- Cell and gene therapy spending year-over-year growth 1 cell and gene therapy
- GIP/GLP-1 agonist spending growth contribution 1 gip glp 1 agonist
- High GDP developed countries medicine spending growth 1
Frequently asked questions
What is the latest obesity-approved GIP and GLP-1 agonist medicine spending growth?
United States: 9.6 billion USD in 2025.
Where does this data come from?
From 1 document published by IQVIA. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Obesity-approved GIP and GLP-1 agonist medicine spending growth [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/obesity-approved-gip-and-glp-1-agonist-medicine-spending-growth
"Obesity-approved GIP and GLP-1 agonist medicine spending growth." StatOrigin, 2026, https://statorigin.org/indicators/obesity-approved-gip-and-glp-1-agonist-medicine-spending-growth. Accessed 28 Oct. 2026.
StatOrigin. "Obesity-approved GIP and GLP-1 agonist medicine spending growth." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/obesity-approved-gip-and-glp-1-agonist-medicine-spending-growth.
@misc{statorigin_obesity_approved_gip_and_glp_1_agonist_medicine_spending_growth_2026, title = {Obesity-approved GIP and GLP-1 agonist medicine spending growth}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/obesity-approved-gip-and-glp-1-agonist-medicine-spending-growth}, note = {Data set. Accessed 2026-10-28} }